Research programme: tricyclic dextrocannabinoids - Pharmos

Drug Profile

Research programme: tricyclic dextrocannabinoids - Pharmos

Latest Information Update: 22 Jul 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmos Corporation
  • Class Cannabinoids
  • Mechanism of Action Antioxidants; NMDA receptor antagonists; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued CNS disorders

Most Recent Events

  • 13 Jun 2006 Pharmos is seeking development partners for the dextrocannabinoid research programme
  • 17 Apr 2001 Preclinical development for CNS disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top